Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Primary Immune Regulatory Disorder: early-phase trial registry

3 of 3 indexed Primary Immune Regulatory Disorder trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Primary Immune Regulatory Disorder: 3 US clinical trials tracked, 3 recruiting.

Primary Immune Regulatory Disorder is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Paul Szabolcs, running 1 of these trials.

Enrollment posture brief

Registry condition primary-immune-regulatory-disorder

OPEN 3 | RECR 100% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Primary Immune Regulator (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Primary Immune Regulatory Disorder

Primary Immune Regulatory Disorder lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Primary Immune Regulatory Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Primary Immune Regulatory Disorder is recruiting above its size-band peers.

    3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 22

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2

Named interventions

Most-linked intervention names on Primary Immune Regulatory Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Phase 2 Established Dose from prior study, NCT03810196 Device
1 trials
Phase 2 Maximum Tolerated Dose determined in Phase 1 Device
1 trials
Phase 1 Dose Level 3 Device
1 trials
Phase 1 Dose Level 2 Device
1 trials
Phase 1 Dose Level 1 Device
1 trials
Stem Cell Transplant Procedure
1 trials
Fludarabine and Dexamethasone Drug
1 trials
Emapalumab Drug
1 trials

US sites by state

Facility locations filed on Primary Immune Regulatory Disorder trials. A trial with sites in several states counts in each.

Pennsylvania 3 trials
Wisconsin 1 trials
Texas 1 trials
New York 1 trials
New Jersey 1 trials
Georgia 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Primary Immune Regulatory Disorder page

3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Primary Immune Regulatory Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Paul Szabolcs sponsors the most Primary Immune Regulatory Disorder trials on record, review their full trial history before evaluating a specific study. See Paul Szabolcs's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Immune Regulatory Disorder condition card totals 3 registered trials; most-linked intervention Phase 2 Established Dose from prior study, NCT03810196; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.